tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2017-2-100-104tumors-350Research ArticleРЕЗОЛЮЦИЯRESOLUTIONРезолюция по итогам экспертного совета «Перспективы изучения и применения эрибулина при диссеминированном РМЖ»Resolution of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”АртамоноваЕ. В.ArtamonovaE. V.

д.м.н., ведущий научный сотрудник отделения амбулаторной химиотерапии

PhD, the Leading researcher of the outpatient chemotherapy department

artamonovae@mail.ruБолотинаЛ. В.BolotinaL. V.

д.м.н., руководитель отделения химиотерапии

PhD, the Head of the chemotherapy department

lbolotina@yandex.ruГорбуноваВ. А.GorbunovaV. A.

д.м.н., профессор, ведущий научный сотрудник отделения химиотерапии

PhD, the Head of the chemotherapy department

ДемидоваИ. А.DemidovaI. A.

к.м.н., заведующая молекулярно-биологической лабораторией

PhD, the Head of the Molecular genetic laboratory

ЖуковН. В.ZhukovN. V.

д.м.н., руководитель отдела оптимизации лечения подростков и молодежи с онкологическими заболеваниями

доцент кафедры онкологии, гематологии и лучевой терапии 

PhD, the Head of the department of optimization of treatment for adults and children with cancer 

ЖуковаЛ. Г.ZhukovaL. G.

д.м.н., ведущий научный сотрудник отделения химиотерапии и комбинированного лечения злокачественных опухолей

PhD, the Leading researcher of the chemotherapy and combined treatment of malignant tumors department

МанзюкЛ. В.ManzyukL. V.

д.м.н., профессор, ведущий научный сотрудник отделения амбулаторной химиотерапии

Professor, the Leading researcher of the outpatient chemotherapy department

СемиглазоваТ. Ю.SemiglazovaT. Y.

д.м.н., заведующая научным отделом инновационных методов терапевтической онкологии и реабилитации

профессор кафедры онкологии

Professor, the Head of the innovative methods of therapeutic oncology and rehabilitation department

Professor of oncology department

ФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» (РОНЦ им. Н. Н. Блохина), МоскваРоссияN. N. Blokhin Russian Cancer Research Center, MoscowRussian Federation«Московский научно-исследовательский онкологический институт имени П. А. Герцена» - филиал ФГБУ «Национальный медицинский исследовательский радиологический центр», МоскваРоссияP. Herzen Moscow Oncology Research Institute of National Medical Research Radiological Centre, MoscowRussian FederationМосковская клиническая онкологическая больница № 62, МоскваРоссияMoscow City Oncology Hospital № 62, MoscowRussian FederationНациональный научно-практический центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачёва, Москва; «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова», МоскваРоссияDmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow; N. I. Pirogov Russian National Research Medical University (RNRMU), MoscowRussian FederationФГБУ «Научно-исследовательский институт онкологии имени Н. Н. Петрова», Санкт-Петербург; ГБОУ ВО «Северо-Западный государственный медицинский университет имени И. И. Мечникова», Санкт-ПетербургРоссияN. N. Petrov Research Institute of Oncology, Saint Petersburg; North-Western State Medical University named after I. I. Mechnikov, Saint PetersburgRussian Federation20172007201702100104Copyright © Артамонова Е.В., Болотина Л.В., Горбунова В.А., Демидова И.А., Жуков Н.В., Жукова Л.Г., Манзюк Л.В., Семиглазова Т.Ю., 20172017Артамонова Е.В., Болотина Л.В., Горбунова В.А., Демидова И.А., Жуков Н.В., Жукова Л.Г., Манзюк Л.В., Семиглазова Т.Ю.Artamonova E.V., Bolotina L.V., Gorbunova V.A., Demidova I.A., Zhukov N.V., Zhukova L.G., Manzyuk L.V., Semiglazova T.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/350

Представлены результаты заседания экспертного совета «Перспективы изучения и применения эрибулина при диссеминированном РМЖ», состоявшегося 16 мая 2017 года с целью обсуждения новых данных в отношении механизма действия эрибулина, российского опыта применения препарата в реальной клинической практике и получения экспертного мнения относительно перспективных направлений изучения эрибулина при раке молочной железы. 

The article presents the results of the meeting of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”, held on May 16, 2017, to discuss new data on the eribulin mechanism of action, the Russian experience with eribulin in real clinical practice and obtain expert opinions on the perspectives of study of eribulin use for breast cancer. 

диссеминированный рак молочной железыэрибулинiadvanced breast cancereribulinReferencesИнструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instruktsiya po meditsinskomu primeneniyu preparata Halaven® (RU LP-001782 ot 28.07.2012, s izmeneniyami ot 08.02.2017). (In Russ.)].Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instruktsiya po meditsinskomu primeneniyu preparata Halaven® (RU LP-001782 ot 28.07.2012, s izmeneniyami ot 08.02.2017). (In Russ.)].Towle M. J., Salvato K.A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2, pp. 496–505.Towle M. J., Salvato K.A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2, pp. 496–505.Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105, No. 10, pp. 1334–1342.Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105, No. 10, pp. 1334–1342.Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, No. 11, pp. 1212–1218.Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, No. 11, pp. 1212–1218.Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.Ozawa Y., Okamoto K., Adachi Y. et al. Suppression of Metastasis and Improvement of Drug Distribution by Eribulin Mesylate, EORTC-NCI-AACR, Barcelona, 2014, Vol. 5, p. 17.Ozawa Y., Okamoto K., Adachi Y. et al. Suppression of Metastasis and Improvement of Drug Distribution by Eribulin Mesylate, EORTC-NCI-AACR, Barcelona, 2014, Vol. 5, p. 17.Goto V., Kashiwagi S., Asano Y. et al. Clinical verification of antitumor autoimmune response in eribulin chemotherapy for breast cancer, AACR, 2016 [Abstr. #5127].Goto V., Kashiwagi S., Asano Y. et al. Clinical verification of antitumor autoimmune response in eribulin chemotherapy for breast cancer, AACR, 2016 [Abstr. #5127].Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study, Lancet 2011, Vol. 377, No. 9769, pp. 914–923.Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study, Lancet 2011, Vol. 377, No. 9769, pp. 914–923.Kaufman P.A., Cortes J., Awada A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan, J. Clin. Oncol., 2015, Vol. 33, No. 6, pp. 594–601.Kaufman P.A., Cortes J., Awada A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan, J. Clin. Oncol., 2015, Vol. 33, No. 6, pp. 594–601.Pivot X., Marme F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.Pivot X., Marme F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.Twelves C. et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an openlabel, phase 2 dose-confirmation study. Presented at SABCS 2014, Abstract #P3-13-04.Twelves C. et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an openlabel, phase 2 dose-confirmation study. Presented at SABCS 2014, Abstract #P3-13-04.Wilks S., Puhalla S., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.Wilks S., Puhalla S., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.Araki K. et al. Eribulin Should be a Candidate Strategy in Combination with Pertuzumab Plus Trastuzumab for Taxane Pretreated HER2-Positive Advance Breast Cancer, SABCS, 2016 [Abstr. P5-15-11].Araki K. et al. Eribulin Should be a Candidate Strategy in Combination with Pertuzumab Plus Trastuzumab for Taxane Pretreated HER2-Positive Advance Breast Cancer, SABCS, 2016 [Abstr. P5-15-11].Hardy-Bessard A., Brocard F., Leheurteur M. et al. ESMERALDA: Phase II trial evaluating the combination of eribulin (E) + bevacizumab (BEV) as first line chemotherapy in patients with metastatic HER2-negative breast cancer (MBC): a GINECO group study, ESMO, 2016 [Abstr. #3730].Hardy-Bessard A., Brocard F., Leheurteur M. et al. ESMERALDA: Phase II trial evaluating the combination of eribulin (E) + bevacizumab (BEV) as first line chemotherapy in patients with metastatic HER2-negative breast cancer (MBC): a GINECO group study, ESMO, 2016 [Abstr. #3730].Tolaney S., Savulsky C., Aktan G. Phase 1b/2 Study to Evaluate Eribulin Mesylate in Combination With Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer, SABCS, 2016 [Abstr. P5-15-02].Tolaney S., Savulsky C., Aktan G. Phase 1b/2 Study to Evaluate Eribulin Mesylate in Combination With Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer, SABCS, 2016 [Abstr. P5-15-02].

The authors declare that there are no conflicts of interest present.